Cross David M相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M(1) receptor agonist HTL0018318 in patients with mild-to-moderate Alzheimer's disease

一项针对轻度至中度阿尔茨海默病患者的选择性毒蕈碱M(1)受体激动剂HTL0018318的安全性和初步药效学作用的1b/2a期多中心研究

期刊:Alzheimer's and Dementia: Translational Research and Clinical Interventions

影响因子:6.8

doi:10.1002/trc2.12273

Nathan, Pradeep J; Millais, S Babli; Godwood, Alex; Dewit, Odile; Cross, David M; Liptrot, Janet; Ruparelia, Bharat; Jones, Stephen Paul; Bakker, Geor; Maruff, Paul T; Light, Gregory A; Brown, Alastair J H; Weir, Malcolm Peter; Congreve, Miles; Tasker, Tim

阿尔茨海默症

发表日期：2022

文献求助收藏

Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M(1) receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study

选择性M(1)受体激动剂HTL0018318在健康年轻成人和老年受试者中的安全性、药代动力学和探索性促认知作用：一项多剂量递增研究

期刊:Alzheimers Research & Therapy

影响因子:7.6

doi:10.1186/s13195-021-00816-5

Bakker, Charlotte; Tasker, Tim; Liptrot, Jan; Hart, Ellen P; Klaassen, Erica S; Doll, Robert Jan; Brown, Giles A; Brown, Alastair; Congreve, Miles; Weir, Malcolm; Marshall, Fiona H; Cross, David M; Groeneveld, Geert Jan; Nathan, Pradeep J

发表日期：2021

文献求助收藏

Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M(1) -acetylcholine receptor agonist: A randomized cross-over trial

选择性毒蕈碱型M(1)-乙酰胆碱受体激动剂HTL0009936的安全性、药代动力学和药效学：一项随机交叉试验

期刊:British Journal of Clinical Pharmacology

doi:10.1111/bcp.14872

Bakker, Charlotte; Prins, Samantha; Liptrot, Jan; Hart, Ellen P; Klaassen, Erica S; Brown, Giles A; Brown, Alastair; Congreve, Miles; Weir, Malcolm; Marshall, Fiona H; Stevens, Jasper; Cross, David M; Tasker, Tim; Nathan, Pradeep J; Groeneveld, Geert Jan

发表日期：2021

文献求助收藏

First-in-man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M(1) -receptor partial agonist for the treatment of dementias

首次人体研究旨在调查新型 M(1) 受体部分激动剂 HTL0018318（用于治疗痴呆症）的安全性、药代动力学和探索性药效学。

期刊:British Journal of Clinical Pharmacology

doi:10.1111/bcp.14710

Bakker, Charlotte; Tasker, Tim; Liptrot, Jan; Hart, Ellen P; Klaassen, Erica S; Prins, Samantha; van der Doef, Thalia F; Brown, Giles A; Brown, Alastair; Congreve, Miles; Weir, Malcolm; Marshall, Fiona H; Cross, David M; Groeneveld, Geert Jan; Nathan, Pradeep J

发表日期：2021

文献求助收藏

Safety and Pharmacokinetics of HTL0018318, a Novel M(1) Receptor Agonist, Given in Combination with Donepezil at Steady State: A Randomized Trial in Healthy Elderly Subjects

新型 M(1) 受体激动剂 HTL0018318 与多奈哌齐联合用药在稳态下的安全性和药代动力学：一项针对健康老年受试者的随机试验

期刊:Drugs in Research & Development

影响因子:2.1

doi:10.1007/s40268-021-00352-5

Bakker, Charlotte; van der Aart, Jasper; Labots, Geert; Liptrot, Jan; Cross, David M; Klaassen, Erica S; Dickinson, Steve; Tasker, Tim; Groeneveld, Geert Jan

发表日期：2021

文献求助收藏

The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer.

热休克蛋白 90 抑制剂 AT13387 在体外和体内对非小细胞肺癌均表现出较长的作用时间

期刊:Cancer Science

影响因子:4.3

doi:10.1111/j.1349-7006.2011.02191.x

Graham Brent, Curry Jayne, Smyth Tomoko, Fazal Lynsey, Feltell Ruth, Harada Isobel, Coyle Joe, Williams Brian, Reule Matthias, Angove Hayley, Cross David M, Lyons John, Wallis Nicola G, Thompson Neil T

细胞生物学

发表日期：2012

文献求助收藏